Clinical features and outcomes of posterior reversible encephalopathy syndrome after heart transplantation: a case series

• Published in: Clinical Transplantation and Research 2024, 38(2), , pp.154-162
• Main Authors: Lim, Ji Hoon, Kim, Seok Hyun, Mo, Cheolyong, Kim, Hyun-Woo, Lee, Soo Yong
• Format: Article
• Language: English
• Subjects: Case Report; posterior reversible encephalopathy syndrome; calcineurin inhibitors; heart transplantation; case report; 의학일반
• ISSN: 3022-6783; 3022-7712; 3022-7712
• DOI: 10.4285/ctr.24.0009

Posterior reversible encephalopathy syndrome (PRES) is a rare neurological disease that may be associated with hypertension, autoregulatory failure, and the use of calcineurin inhibitors following heart transplantation (HT). In this article, we present a case series of PRES, discussing its potential causes and management strategies. Among the 126 HT recipients at our hospital, four were diagnosed with PRES. Three of these patients developed PRES within 7 days after HT. Prior to the onset of PRES, all patients experienced sustained hypertension, and strict blood pressure (BP) control was maintained. Three of the four patients recovered without PRES recurrence, while one patient died of sepsis after an episode of altered consciousness. Hypertension was observed in all patients prior to the onset of PRES, and the majority experienced symptom improvement with BP control. While most cases of PRES were reversible with conservative treatment, including the administration of antiepileptics, one irreversible case resulted in in-hospital mortality. Thus, PRES can have serious outcomes and is not invariably benign.